GERN vs KPTI
GERN: First-in-class telomerase inhibitor company with FDA-approved RYTELO for myelodysplastic syndromes, now expanding into myelofibrosis with Phase 3 clinical data pending. KPTI: Karyopharm is a clinical-stage oncology company commercializing XPOVIO, a first-in-class XPO1 inhibitor for multiple myeloma, with ongoing trials in myelofibrosis and endometrial cancer.
Side-by-side fundamentals
| Metric | GERN | KPTI | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $1.41 | $7.18 | |
| Market cap as of 2026-07-23 | $917M | $178M | |
| PEG as of 2026-07-23 | n/a | -0.04 | |
| Net margin as of 2026-07-23 | -34.3% | -129.0% | GERN higher |
| Gross margin as of 2026-07-23 | +97.3% | +96.0% | GERN higher |
| Operating margin as of 2026-07-23 | -26.4% | -97.0% | GERN higher |
| ROE as of 2026-07-23 | -28.0% | -182.4% | GERN higher |
| ROA as of 2026-07-23 | -12.1% | -176.9% | GERN higher |
| Debt / equity as of 2026-07-23 | 1.09 | 3.78 | GERN lower |
| Revenue growth (YoY) as of 2026-07-23 | +68.6% | +6.3% | GERN higher |
| Revenue CAGR (3y) SEC XBRL | -2.2% | -2.4% | GERN higher |
| Beta as of 2026-07-23 | 0.58 | 0.89 | |
| 1-year return as of 2026-07-22 close | +17.1% | +84.6% | KPTI higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.